This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Aug;11(8):423.

doi: 10.1038/nrurol.2014.173. Epub 2014 Jul 15.

Prostate cancer: Phasing in new treatment

PMID: 25023597
DOI: 10.1038/nrurol.2014.173

Comment

Prostate cancer: Phasing in new treatment

Louise Stone. Nat Rev Urol. 2014 Aug.

. 2014 Aug;11(8):423.

doi: 10.1038/nrurol.2014.173. Epub 2014 Jul 15.

Author

PMID: 25023597
DOI: 10.1038/nrurol.2014.173

No abstract available

PubMed Disclaimer

Comment on

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, Garcia JA, Protheroe A, Tammela TL, Elliott T, Mattila L, Aspegren J, Vuorela A, Langmuir P, Mustonen M; ARADES study group. Fizazi K, et al. Lancet Oncol. 2014 Aug;15(9):975-85. doi: 10.1016/S1470-2045(14)70240-2. Epub 2014 Jun 25. Lancet Oncol. 2014. PMID: 24974051 Clinical Trial.

References

1. Lancet Oncol. 2014 Aug;15(9):975-85 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information